The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

She was happily married, pregnant with her first child and had recently completed her residency in family medicine. Soon ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...